Improving glaucoma care in underserved communities
Official title: Ocuelar: Revolutionizing Glaucoma Management in Medically Underserved Communities
Funded at 231 Sheep LLC · NIH-10923424 · Data updated 2026-11-12
This study is all about finding better ways to help people with glaucoma, especially in communities that don’t always get the care they need, by using new tools and technology to make it easier for patients to stick to their treatment and stay in touch with their doctors.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 231 Sheep LLC NIH-funded |
| Lab location | 1 site (San Gabriel, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $301,941 |
| NIH project number | 1R43AG088139-01 |
| Project ID | NIH-10923424 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals from medically underserved communities, particularly those at risk for glaucoma.
✕Less likely to help
Patients who do not have glaucoma or are not part of medically underserved communities may not receive benefit from this research.
What this research studies
This research focuses on enhancing the management of glaucoma, particularly in medically underserved communities. It aims to develop innovative tools and strategies to improve patient adherence to treatment and follow-up care. By leveraging technology and community engagement, the project seeks to address barriers faced by diverse populations, including African American and Asian communities, in accessing effective glaucoma management. The approach includes the use of computer software to track patient data and improve communication between patients and healthcare providers.
Why it matters
Potential benefit: If successful, this research could lead to better glaucoma management and reduced risk of blindness for patients in underserved communities.
How similar studies have gone: Other research has shown success in using technology to improve adherence and management of chronic conditions in underserved populations, indicating a promising approach.
Where this research is happening
-
231 Sheep LLC
San Gabriel, United States Active
Researchers
- Principal investigator: Lee, Scott — 231 Sheep LLC
- Study coordinator: Lee, Scott
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Comparing tube positions in glaucoma implants to protect corneal cells
This trial compares two tube placements for glaucoma drainage implants to see which better protects corneal cells and controls eye pressure in people with uncontrolled glaucoma.
-
Automated topographic test for glaucoma detection and progression
A new automated method uses topographic structure-function mapping to help diagnose glaucoma earlier and track its progression in patients.
-
Using AI on eye scans and genes to predict glaucoma risk
This project uses artificial intelligence on eye scans, vision tests, and genetic information to find people most likely to develop or have worsening glaucoma.
-
AI-based glaucoma screening in community health centers
A new, easy-to-use AI screening approach will be tested in federally funded health centers to help identify people at risk for glaucoma, especially in communities with higher risk.
-
Understanding how glaucoma genes control eye cell function
A long-term research project will study how genetic factors affect eye cells in adults with glaucoma to uncover new ideas for protecting vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.